Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Êîñìåòîëîãèÿ-äåðìàòîëîãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-äåðìàòîâåíåðîëîãîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 29.11.2009, 02:11
Àâàòàð äëÿ Annabella
Annabella Annabella âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 22.01.2006
Ãîðîä: Ïåòðîçàâîäñê
Ñîîáùåíèé: 20,501
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 4,696 ðàç(à) çà 3,659 ñîîáùåíèé
Annabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äîêòîð, Âû âåñüìà íðàâîó÷èòåëüíûì òîíîì ðàññêàçûâàåòå çäåñü íàì î òîì, êàêèå áûâàþò èììóíîäåôèöèòû, è ñïðàøèâàåòå ïðî ñåðîíåãàòèâíîå îêíî?
ß âïîëíå ïîíèìàþ, ÷òî îá ýòîì íå ìîãóò çíàòü ïàöèåíòû, íî ÷òîáû âðà÷, êîòîðûé òàê óâåðåííî ïîó÷àåò êîëëåã?
Âû íå ïðîáîâàëè ïîëüçîâàòüñÿ õîòÿ áû ßíäåêñîì?
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ïðÿìî äàæå íåóäîáíî...
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 29.11.2009, 03:10
FBN FBN âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 16.11.2009
Ãîðîä: ã. Ãàò÷èíà
Ñîîáùåíèé: 1,727
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 731 ðàç(à) çà 699 ñîîáùåíèé
FBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Annabella Ïîñìîòðåòü ñîîáùåíèå
Äîêòîð, Âû âåñüìà íðàâîó÷èòåëüíûì òîíîì ðàññêàçûâàåòå çäåñü íàì î òîì, êàêèå áûâàþò èììóíîäåôèöèòû, è ñïðàøèâàåòå ïðî ñåðîíåãàòèâíîå îêíî?
ß âïîëíå ïîíèìàþ, ÷òî îá ýòîì íå ìîãóò çíàòü ïàöèåíòû, íî ÷òîáû âðà÷, êîòîðûé òàê óâåðåííî ïîó÷àåò êîëëåã?
Âû íå ïðîáîâàëè ïîëüçîâàòüñÿ õîòÿ áû ßíäåêñîì?
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ïðÿìî äàæå íåóäîáíî...
Âî-ïåðâûõ, ÿ èçëîæèë ñâîè ðàññóæäåíèÿ, à íå ïîó÷àë íèêîãî "âåñüìà íðàâîó÷èòåëüíûì òîíîì". Ýòî Âû ïûòàåòåñü ïîó÷àòü íðàâîó÷èòåëüíûì òîíîì.
Âî-âòîðûõ, ÿ ïèñàë, ÷òî:
Öèòàòà:
... àíòèòåëà îáíàðóæèâàþòñÿ â òå÷åíèå âñåãî ïåðèîäà èíôåêöèè, è ìîãóò íå îáíàðóæèâàòüñÿ òîëüêî â ïåðâûå ìåñÿöû çàðàæåíèÿ èëè â òåðìèíàëüíîé ñòàäèè çàáîëåâàíèÿ...
ß ïðîñòî íå ñëûøàë (ìîæåò íå îòëîæèëîñü â ïàìÿòè) è íå âñòðå÷àë ðàíüøå â ëèòåðàòóðå ïî ýòîé òåìå, ÷òî ýòîò ïåðèîä íàçûâàþò "ñåðîíåãàòèâíîå îêíî".

Â-òðåòüèõ. Êàê Âû ñåáå ïðåäñòàâëÿåòå òàêóþ ñèòóàöèþ, ÷òî ó áîëüíîãî óæå óñïåë ðàçâèòüñÿ ÑÏÈÄ, åñëè ñ ìîìåíòà çàðàæåíèÿ ïðîøëî åùå òàê ìàëî âðåìåíè, ÷òî äàæå àíòèòåëà ê ÂÈ× åùå íå óñïåëè ïîÿâèòüñÿ?

Â-÷åòâåðòûõ:
Öèòàòà:
Ñîîáùåíèå îò Annabella Ïîñìîòðåòü ñîîáùåíèå
Ìíå äîâîëüíî ÷àñòî ïðèõîäèòñÿ âèäåòü áîëüíûõ, êîòîðûå îêàçûâàþòñÿ â íàøåì çàâåäåíèè ñ âíåëåãî÷íûìè ôîðìàìè òóáåðêóëåçà èìåííî â òîì ñàìîì ñåðîíåãàòèâíîì îêíå, êîòîðîå íå äàåò ïîëîæèòåëüíîé ÈÔÀ ÀÒ ê ÂÈ×, ïðè ýòîì ó ïàöèåíòîâ ÂÍ ïîä ìèëëèîí è CD4+ 80-200 êë/ìë, ÷òî ÿâëÿåòñÿ êðèòè÷åñêèì óðîâíåì.
Ïî ïðèâåäåííûì Âàìè ññûëêàì âåçäå ïèøóò: ÑÅÐÎÍÅÃÀÒÈÂÍÎÅ ÎÊÍÎ ïðè ÂÈ×-èíôåêöèè: ïåðèîä ñ ìîìåíòà çàðàæåíèÿ äî ïîÿâëåíèÿ àíòèòåë.
Òî åñòü, Âû óòâåðæäàåòå, ÷òî ó áîëüíîãî óæå óñïåë ðàçâèòüñÿ ÑÏÈÄ, à îí âñå åùå íàõîäèòñÿ â òîì ñàìîì ñåðîíåãàòèâíîì îêíå?
Èëè ýòî óæå òåðìèíàëüíàÿ ñòàäèÿ çàáîëåâàíèÿ, è òîãäà âîçíèêàåò âîïðîñ: ïðè÷åì òóò ýòî ñåðîíåãàòèâíîå îêíî?
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 29.11.2009, 23:09
Àâàòàð äëÿ Annabella
Annabella Annabella âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 22.01.2006
Ãîðîä: Ïåòðîçàâîäñê
Ñîîáùåíèé: 20,501
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 4,696 ðàç(à) çà 3,659 ñîîáùåíèé
Annabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnnabella ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íó à òåïåðü åñëè ñåðüåçíî. ß çàãëÿíóëà â òåìó ïî ïðîñüáå Àíàñòàñèè, òàê êàê èìåþ îïðåäåëåííîå îáðàçîâàíèå â îáëàñòè ÂÈ×-èíôåêöèè è äîâîëüíî äàâíî (ïî ðîññèéñêèì ìåðêàì, êîíå÷íî) ðàáîòàþ ñ òàêèìè ïàöèåíòàìè.
Ïðåäëàãàþ äëÿ íà÷àëà ïî÷èòàòü òî, ÷òî åñòü ñåé÷àñ íà ðóññêîì ÿçûêå è â áåñïëàòíîì äîñòóïå:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Íà ñåãîäíÿ ýòî âïîëíå äîñòàòî÷íûé îáúåì èíôîðìàöèè, êîòîðûé íóæåí ëþáîìó âðà÷ó, êîòîðûé ìîæåò èìåòü äåëî ñ ÂÈ×-èíôåêöèåé.

(Âîçìîæíî, ìíå ïîêàçàëîñü, íî öåëüþ äàííîãî ôîðóìà íå ÿâëÿåòñÿ èçðå÷åíèå èñòèí, à ïîëó÷åíèå èíôîðìàöèè è îáñóæäåíèå åå ñ êîëëåãàìè).
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 30.11.2009, 09:10
Àâàòàð äëÿ dr.Agapov
dr.Agapov dr.Agapov âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.09.2004
Ãîðîä: ã.Ðîñòîâ-íà-Äîíó
Ñîîáùåíèé: 2,554
Ïîáëàãîäàðèëè 226 ðàç(à) çà 185 ñîîáùåíèé
dr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådr.Agapov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FBN Ïîñìîòðåòü ñîîáùåíèå
Âî-ïåðâûõ, ÿ èçëîæèë ñâîè ðàññóæäåíèÿ, à íå ïîó÷àë íèêîãî "âåñüìà íðàâîó÷èòåëüíûì òîíîì". Ýòî Âû ïûòàåòåñü ïîó÷àòü íðàâîó÷èòåëüíûì òîíîì.
Âî-âòîðûõ, ÿ ïèñàë, ÷òî:

ß ïðîñòî íå ñëûøàë (ìîæåò íå îòëîæèëîñü â ïàìÿòè) è íå âñòðå÷àë ðàíüøå â ëèòåðàòóðå ïî ýòîé òåìå, ÷òî ýòîò ïåðèîä íàçûâàþò "ñåðîíåãàòèâíîå îêíî".

Â-òðåòüèõ. Êàê Âû ñåáå ïðåäñòàâëÿåòå òàêóþ ñèòóàöèþ, ÷òî ó áîëüíîãî óæå óñïåë ðàçâèòüñÿ ÑÏÈÄ, åñëè ñ ìîìåíòà çàðàæåíèÿ ïðîøëî åùå òàê ìàëî âðåìåíè, ÷òî äàæå àíòèòåëà ê ÂÈ× åùå íå óñïåëè ïîÿâèòüñÿ?

Â-÷åòâåðòûõ:

Ïî ïðèâåäåííûì Âàìè ññûëêàì âåçäå ïèøóò: ÑÅÐÎÍÅÃÀÒÈÂÍÎÅ ÎÊÍÎ ïðè ÂÈ×-èíôåêöèè: ïåðèîä ñ ìîìåíòà çàðàæåíèÿ äî ïîÿâëåíèÿ àíòèòåë.
Òî åñòü, Âû óòâåðæäàåòå, ÷òî ó áîëüíîãî óæå óñïåë ðàçâèòüñÿ ÑÏÈÄ, à îí âñå åùå íàõîäèòñÿ â òîì ñàìîì ñåðîíåãàòèâíîì îêíå?
Èëè ýòî óæå òåðìèíàëüíàÿ ñòàäèÿ çàáîëåâàíèÿ, è òîãäà âîçíèêàåò âîïðîñ: ïðè÷åì òóò ýòî ñåðîíåãàòèâíîå îêíî?
Âû ñ îäíîé ñòîðîíû ïðàâû,ñ äðóãîé íåò.
Êîíå÷íî AIDS - êàê äèàãíîç ïðè îòñóòñòâèè àíòèòåë íå ñòàâèòñÿ,íî âñå äåëî â òîì,÷òî â ïåðèîä ñåðîêîíâåðñèè (seroconversion) - ñåé÷àñ ïîëüçóþòñÿ òàêèì òåðìèíîì(êîòîðàÿ áûâàåò àññèìïòîìíàÿ è îñòðàÿ) - ìîæåò íàáëþäàòüñÿ òàê íàçûâàåìàÿ îñòðàÿ èììóíîñóïðåññèÿ (Acute immunosuppression),÷òî âåäåò ê âðåìåííîìó óìåíüøåíèþ ÑD4+ ëèìôîöèòîâ (òàê êàê îíè ÿâëÿþòñÿ êëåòêàìè-ìèøåíÿìè ÂÈ×), èíîãäà äî óðîâíÿ, äîñòàòî÷íîãî äëÿ ðàçâèòèÿ îïïîðòóíèñòè÷åñêèõ èíôåêöèé â ýòîé ôàçå .
Òàêèõ ñëó÷àåâ îïèñàíî ìàëî (êîíòàãèîçíûé ìîëëþñê íå îïèñàí),íàïðèìåð
îïèñàí ÖÌÂ àññîöèèðîâàííûé êîëèò
Gupta(1993) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ïíåâìîöèñòíàÿ ïíåâìîíèÿ
Vento S (1993)[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Êîíå÷íî ìîæåò âñòðå÷àòüñÿ èäèîïàòè÷åñêàÿ CD4+ ëèìôîöèòîïåíèÿ (Idiopathic CD4+ lymphocytopenia),íî ðàçâèòèå íåîáû÷íûõ èíôåêöèé íåõàðàêòåðíîé ëîêàëèçàöèè è â íåõàðàêòåðíîì âîçðàñòå äîëæíà íàñòîðàæèâàòü â îòíîøåíèè ÂÈ×.

Êîììåíòàðèè ê ñîîáùåíèþ:
Annabella îäîáðèë(à):
Dr.Anisimova îäîáðèë(à):
Anton Verbine îäîáðèë(à): ...ja tozhe poiskal sluchai "molljuska" pri serokonversii i ne nashel
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 30.11.2009, 17:42
Anton Verbine Anton Verbine âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 15.12.2006
Ãîðîä: Moscow-Princeton-Vicenza-Toronto-Moscow
Ñîîáùåíèé: 2,022
Ïîáëàãîäàðèëè 168 ðàç(à) çà 155 ñîîáùåíèé
Anton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
âîò åøå ïàðà ññûëîê äëÿ èíòåðåñà
ìîëëþñê ïðè ÂÈ× [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
ìîëëþñê ïðè èììóííîé ðå-êîíñòèòóöèè (íà÷àëî ÕÀÀÐÒ) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Anisimova îäîáðèë(à): ñïàñèáî, ÷èòàåì...
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 30.11.2009, 20:01
FBN FBN âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 16.11.2009
Ãîðîä: ã. Ãàò÷èíà
Ñîîáùåíèé: 1,727
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 731 ðàç(à) çà 699 ñîîáùåíèé
FBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Annabella Ïîñìîòðåòü ñîîáùåíèå
Íó à òåïåðü åñëè ñåðüåçíî. ß çàãëÿíóëà â òåìó ïî ïðîñüáå Àíàñòàñèè, òàê êàê èìåþ îïðåäåëåííîå îáðàçîâàíèå â îáëàñòè ÂÈ×-èíôåêöèè è äîâîëüíî äàâíî (ïî ðîññèéñêèì ìåðêàì, êîíå÷íî) ðàáîòàþ ñ òàêèìè ïàöèåíòàìè.
Ïðåäëàãàþ äëÿ íà÷àëà ïî÷èòàòü òî, ÷òî åñòü ñåé÷àñ íà ðóññêîì ÿçûêå è â áåñïëàòíîì äîñòóïå:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Íà ñåãîäíÿ ýòî âïîëíå äîñòàòî÷íûé îáúåì èíôîðìàöèè, êîòîðûé íóæåí ëþáîìó âðà÷ó, êîòîðûé ìîæåò èìåòü äåëî ñ ÂÈ×-èíôåêöèåé.

(Âîçìîæíî, ìíå ïîêàçàëîñü, íî öåëüþ äàííîãî ôîðóìà íå ÿâëÿåòñÿ èçðå÷åíèå èñòèí, à ïîëó÷åíèå èíôîðìàöèè è îáñóæäåíèå åå ñ êîëëåãàìè).
Âû íå îòâåòèëè íà çàäàííûå âîïðîñû, êàñàþùèåñÿ Âàøèõ óòâåðæäåíèé â ïðåäûäóùèõ ïîñòàõ, è âìåñòî ýòîãî îòñûëàåòå íà ñàéò ñ èíôîðìàöèåé ïî ÂÈ× è ÑÏÈÄ. ß åãî ïðîñìîòðåë, íî ïîäòâåðæäåíèé Âàøèõ óòâåðæäåíèé òàì íå íàøåë. Ëó÷øå â òàêèõ ñëó÷àÿõ òêíóòü íîñîì â êîíêðåòíóþ ññûëêó, èëè ïðèâåñòè öèòàòó.
PS: Èíôîðìàöèþ ïî ÂÈ× è ÑÏÈÄ ñåé÷àñ â èíòåðíåòå íàéòè íå òðóäíî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 01.12.2009, 01:32
FBN FBN âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 16.11.2009
Ãîðîä: ã. Ãàò÷èíà
Ñîîáùåíèé: 1,727
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 731 ðàç(à) çà 699 ñîîáùåíèé
FBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò dr.Agapov Ïîñìîòðåòü ñîîáùåíèå
Âû ñ îäíîé ñòîðîíû ïðàâû,ñ äðóãîé íåò.
Êîíå÷íî AIDS - êàê äèàãíîç ïðè îòñóòñòâèè àíòèòåë íå ñòàâèòñÿ,íî âñå äåëî â òîì,÷òî â ïåðèîä ñåðîêîíâåðñèè (seroconversion) - ñåé÷àñ ïîëüçóþòñÿ òàêèì òåðìèíîì(êîòîðàÿ áûâàåò àññèìïòîìíàÿ è îñòðàÿ) - ìîæåò íàáëþäàòüñÿ òàê íàçûâàåìàÿ îñòðàÿ èììóíîñóïðåññèÿ (Acute immunosuppression),÷òî âåäåò ê âðåìåííîìó óìåíüøåíèþ ÑD4+ ëèìôîöèòîâ (òàê êàê îíè ÿâëÿþòñÿ êëåòêàìè-ìèøåíÿìè ÂÈ×), èíîãäà äî óðîâíÿ, äîñòàòî÷íîãî äëÿ ðàçâèòèÿ îïïîðòóíèñòè÷åñêèõ èíôåêöèé â ýòîé ôàçå .
Òàêèõ ñëó÷àåâ îïèñàíî ìàëî (êîíòàãèîçíûé ìîëëþñê íå îïèñàí),íàïðèìåð
îïèñàí ÖÌÂ àññîöèèðîâàííûé êîëèò
Gupta(1993) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ïíåâìîöèñòíàÿ ïíåâìîíèÿ
Vento S (1993)[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Êîíå÷íî ìîæåò âñòðå÷àòüñÿ èäèîïàòè÷åñêàÿ CD4+ ëèìôîöèòîïåíèÿ (Idiopathic CD4+ lymphocytopenia),íî ðàçâèòèå íåîáû÷íûõ èíôåêöèé íåõàðàêòåðíîé ëîêàëèçàöèè è â íåõàðàêòåðíîì âîçðàñòå äîëæíà íàñòîðàæèâàòü â îòíîøåíèè ÂÈ×.
Êîíòàãèîçíûé ìîëëþñê ó âçðîñëûõ, âåäóùèõ ñåêñóàëüíî àêòèâíûé îáðàç æèçíè, íå òàêîå óæ ðåäêîå çàáîëåâàíèå, êîòîðîå ïåðåäàåòñÿ ïðåèìóùåñòâåííî ïðè ïîëîâûõ êîíòàêòàõ. Ñàì, ëè÷íî, íàáëþäàë äåñÿòêè òàêèõ ïàöèåíòîâ çà ñâîþ ïðàêòèêó (èíîãäà ñ ìíîæåñòâåííûìè âûñûïàíèÿìè). Çàðóáåæíûå èñòî÷íèêè òîæå ïîäòâåðæäàþò ýòî:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
Age.
Molluscum contagiosum appears to have a bimodal age distribution. The first is in childhood, when transmission occurs from nonsexual skin contact. The second is in early adulthood (age 15-29 y), when molluscum contagiosum occurs as a sexually transmitted disease.
Íàéäåííûå Âàìè îïèñàíèÿ 2 ñëó÷àåâ îïïîðòóíèñòè÷åñêèõ èíôåêöèé â ïåðèîä ñåðîêîíâåðñèè, ñâÿçàííûå ñ âîçíèêíîâåíèåì ò.í. îñòðîé èììóíîñóïðåññèè, ìîæíî ñ÷èòàòü ñêîðåå êàçóèñòèêîé, ÷åì ðàñïðîñòðàíåííûì ÿâëåíèåì, åñëè ó÷åñòü òîò ôàêò, ÷òî äàæå â äîñòàòî÷íî ðàçâèòûõ ñòðàíàõ åæåãîäíî ðåãèñòðèðóþò ìíîãèå ìèëëèîíû âíîâü çàáîëåâøèõ ÂÈ×.

Îïèñàííûå 2 ñëó÷àÿ èíôåêöèè îòíîñÿòñÿ ê ò.í. îïïîðòóíèñòè÷åñêèì èíôåêöèÿì. Êîíòàãèîçíûé ìîëëþñê, â îòëè÷èå îò îïèñàííûõ âûøå 2 èíôåêöèé, íå îòíîñèòñÿ ê îïïîðòóíèñòè÷åñêèì èíôåêöèÿì, ò.ê. õîòü è âñòðå÷àåòñÿ â íåñêîëüêî ðàç ÷àùå (ó ïðèìåðíî 8% áîëüíûõ ÑØÀ, ñì. ïî ññûëêå ïðèâåäåííîé âûøå), äîâîëüíî ÷àñòî âñòðå÷àåòñÿ è ñðåäè ëþäåé áåç èììóíîäåôèöèòà.

Ãèïîòåòè÷åñêè ìîæíî ñòðîèòü ëþáûå òåîðèè è ïðåäïîëîæåíèÿ. Íî ìû íà ýòîì ñàéòå òâåðäèì, ÷òî íóæíî îïèðàòüñÿ íà äîêàçàòåëüñòâà (íà äîêàçàòåëüíóþ ìåäèöèíó). Òàê ÷òî, äàâàéòå ïîêà áóäåì èñõîäèòü èç òîãî ôàêòà, ÷òî äî íàñòîÿùåãî âðåìåíè íå îïèñàíî íè îäíîãî ñëó÷àÿ êîíòàãèîçíîãî ìîëëþñêà, àññîöèèðîâàííîãî ñ ò.í. îñòðîé èììóíîñóïðåññèåé âî âðåìÿ ïåðèîäà ñåðîêîíâåðñèè. Òî åñòü, ñàìà âîçìîæíîñòü ñóùåñòâîâàíèÿ îïèñàííîé âûøå ñèòóàöèè äî íàñòîÿùåãî âðåìåíè íè ðàçó íå äîêàçàíà, íåñìîòðÿ íà áîëüøîå ÷èñëî íàáëþäåíèé çà çàáîëåâøèìè ÂÈ×.
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 01.12.2009, 01:45
FBN FBN âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 16.11.2009
Ãîðîä: ã. Ãàò÷èíà
Ñîîáùåíèé: 1,727
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 731 ðàç(à) çà 699 ñîîáùåíèé
FBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Anton Verbine Ïîñìîòðåòü ñîîáùåíèå
âîò åøå ïàðà ññûëîê äëÿ èíòåðåñà
ìîëëþñê ïðè ÂÈ× [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
ìîëëþñê ïðè èììóííîé ðå-êîíñòèòóöèè (íà÷àëî ÕÀÀÐÒ) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ñïàñèáî çà ññûëêè! Ñåé÷àñ åñòü äîñòàòî÷íî ìíîãî èíôîðìàöèè î êîíòàãèîçíîì ìîëëþñêå ïðè ÂÈ×. Îá ýòîì íèêòî íå ñïîðèò, ÷òî êîíòàãèîçíûé ìîëëþñê â íåñêîëüêî ðàç ÷àùå âñòðå÷àåòñÿ ïðè ÑÏÈÄ.

Äèñêóññèÿ èçíà÷àëüíî èäåò î òîì, ìîæåò ëè áûòü ÑÏÈÄ ó áîëüíîé, ïðè îòñóòñòâèè àíòèòåë ê ÂÈ× (âî âðåìÿ ò.í. ïåðèîäà ñåðîêîíâåðñèè), è ñ îáèëüíûìè ñâåæèìè âûñûïàíèÿìè êîíòàãèîçíîãî ìîëëþñêà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 01.12.2009, 16:34
Anton Verbine Anton Verbine âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 15.12.2006
Ãîðîä: Moscow-Princeton-Vicenza-Toronto-Moscow
Ñîîáùåíèé: 2,022
Ïîáëàãîäàðèëè 168 ðàç(à) çà 155 ñîîáùåíèé
Anton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnton Verbine ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FBN Ïîñìîòðåòü ñîîáùåíèå
Ñïàñèáî çà ññûëêè! Ñåé÷àñ åñòü äîñòàòî÷íî ìíîãî èíôîðìàöèè î êîíòàãèîçíîì ìîëëþñêå ïðè ÂÈ×. Îá ýòîì íèêòî íå ñïîðèò, ÷òî êîíòàãèîçíûé ìîëëþñê â íåñêîëüêî ðàç ÷àùå âñòðå÷àåòñÿ ïðè ÑÏÈÄ.

Äèñêóññèÿ èçíà÷àëüíî èäåò î òîì, ìîæåò ëè áûòü ÑÏÈÄ ó áîëüíîé, ïðè îòñóòñòâèè àíòèòåë ê ÂÈ× (âî âðåìÿ ò.í. ïåðèîäà ñåðîêîíâåðñèè), è ñ îáèëüíûìè ñâåæèìè âûñûïàíèÿìè êîíòàãèîçíîãî ìîëëþñêà.
ß, ñîáñòâåííî, íè ñ êåì íå äèñêóòèðóþ, âî âñÿêîì ñëó÷àå â "îòêðûòîé" ÷àñòè ôîðóìà â åòîé òåìå. ß ïðèâ¸ë 2 ññûëêè, êîòîðûå ìîãóò îêàçàòüñÿ ïîëåçíûìè òåì, êîãî ïî çàïðîñó- "ìîëëþñê è ÂÈ×" ïîèñê ïðèâåäåò íà åòó ñòðàíèöó
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 06.12.2009, 01:17
FBN FBN âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 16.11.2009
Ãîðîä: ã. Ãàò÷èíà
Ñîîáùåíèé: 1,727
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 731 ðàç(à) çà 699 ñîîáùåíèé
FBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFBN ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
×òîáû íå âûçûâàòü ñîìíåíèé ó ïàöèåíòêè, ðåøèë çàïîñòèòü ýòó èíôîðìàöèþ çäåñü (â çàêðûòîì ðàçäåëå).
Èíôîðìàöèÿ îò FDA ïî ýôôåêòèâíîñòè ëå÷åíèÿ êîíòàãèîçíîãî ìîëëþñêà (ó äåòåé) êðåìîì Àëäàðà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
8.4. 8.4 Pediatric Use
......
Aldara Cream was evaluated in two randomized, vehicle-controlled, double-blind trials involving 702 pediatric subjects with molluscum contagiosum (MC) (470 exposed to Aldara; median age 5 years, range 2-12 years). Subjects applied Aldara Cream or vehicle 3 times weekly for up to 16 weeks. Complete clearance (no MC lesions) was assessed at Week 18. In Study 1, the complete clearance rate was 24% (52/217) in the Aldara Cream group compared with 26% (28/106) in the vehicle group. In Study 2, the clearance rates were 24% (60/253) in the Aldara Cream group compared with 28% (35/126) in the vehicle group. These studies failed to demonstrate efficacy.
Ïîëàãàþ, ÷òî ýòè ðåçóëüòàòû ìîæíî ýêñòðàïîëèðîâàòü è íà âçðîñëûõ ïàöèåíòîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 06.12.2009, 14:07
Àâàòàð äëÿ nastassia
nastassia nastassia âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 22.01.2006
Ãîðîä: ìîñêâà
Ñîîáùåíèé: 9,581
Ïîáëàãîäàðèëè 2,614 ðàç(à) çà 2,362 ñîîáùåíèé
nastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìånastassia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
îäîáðÿëêè çàêîí÷èëèñü. ñïàñèáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 06.12.2009, 15:28
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- ïðèñîåäèíÿþñü ê Íàñòå, åñòü ÷òî ïî÷èòàòü, ñïàñèáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 06.12.2009, 16:40
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- ýòî æå åñòü è çäåñü:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Imiquimod (Aldara)
Induces secretion of cytokines, including interferon-alpha, TNF, and interleukins; increases T-cell activity. Minimal immediate antiviral activity. May be more effective in women than in men. Use 5% cream.
- ýòè äàííûå óæå åñòü â êëèí. ðóêîâîäñòâàõ:
"Ïîëàãàþ, ÷òî ýòè ðåçóëüòàòû ìîæíî ýêñòðàïîëèðîâàòü è íà âçðîñëûõ ïàöèåíòîâ."
- ó âçðîñëûõ-äà â ïëàíå ýôôåêòèâíîñòè, ó äåòåé - íåò, âñå âåðíî
"Administer as in adults; efficacy not demonstrated in children aged 2-12 y"
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 06.12.2009, 16:55
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- ìåòà-àíàëèç êîêðàíîâñêèé:
"Interventions for cutaneous molluscum contagiosum"
Authors' conclusions
- îäíîçíà÷íûõ íà ýòîì óðîâíå ïîêà íåò:
No single intervention has been shown to be convincingly effective in the treatment of molluscum contagiosum. The update identified six new studies, most of them reporting on interventions not included in the original version. However, the conclusions of the review did not change.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 06.12.2009, 17:02
Dr.Anisimova Dr.Anisimova âíå ôîðóìà ÂÐÀ×
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 16.01.2007
Ãîðîä: ÐÔ
Ñîîáùåíèé: 14,319
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 5,347 ðàç(à) çà 4,983 ñîîáùåíèé
Dr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Anisimova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- âîò èç ïîñëåäíèõ ó äåòåé:
Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
"To compare the efficacy, safety and acceptability of imiquimod (IMQ) 5% cream with cryotherapy for the treatment of molluscum contagiosum (MC) in children. Prospective, randomized, comparative, observer blinded study. A total of 74 children, with MC were divided randomly to receive treatment with either IMQ 5% cream (group A) 5 days a week or cryotherapy (group B) once a week until clinical cure or up to a maximum of 16 weeks. All the patients were followed up weekly during active treatment. The patients were followed-up for 6 months after clinical cure to look for recurrence. In the IMQ group (group A), the overall complete cure rate was 91.8% (34 of 37), 22 of the 37 patients cleared by the end of 6 weeks and 12 more patients cleared by the end of 12 weeks, while the remaining three patients (8.1%) did not clear even after 16 weeks. Whereas, in the cryotherapy group, all 37 patients achieved complete cure, 26 of 37 (70.27%) patients cleared after 3 weeks, and the remaining 11 (29.72%) cleared by the end of 6 weeks. No statistically significant difference was found between the overall complete cure rate in both groups at the end of maximum treatment period (16 weeks). Pain, bullae formation, pigmentary changes, and superficial scarring were more significantly common in the cryotherapy group compared with the IMQ group. Imiqimod 5% cream seems to be slow acting but an effective agent for the treatment of MC in children. IMQ appears to be practically painless and more cosmetically accepted treatment when compared with cryotherapy, and may be the preferred treatment of MC in children especially with numerous small lesions. Cryotherapy has the advantage of being rapidly effective, and is less expensive than IMQ and may be the preferred treatment for large solitary or few lesions."
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:29.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.